If you have shopped for compounded semaglutide, you have seen the terms 503A and 503B, usually dropped into a paragraph about safety without explanation. They refer to two different categories of compounding pharmacy under federal law, and the difference genuinely matters — though not always in the direction the marketing implies.
The Short Answer
503A pharmacies compound medication for an individual patient against a specific prescription. 503B outsourcing facilities compound in larger batches, may produce without patient-specific prescriptions, and register with the FDA, which inspects them and holds them to manufacturing standards. Neither produces an FDA-approved drug — the FDA does not review compounded products for safety or effectiveness in either case.
503A: Traditional Compounding
This is the older, more familiar model — a pharmacy preparing a customised medication for a named patient because the commercial product does not suit them. Think a liquid version for someone who cannot swallow tablets, or a formulation without a particular dye.
- Compounds against an individual, patient-specific prescription
- Regulated primarily by state boards of pharmacy, not the FDA
- Not required to follow the full manufacturing standards that apply to drug makers
- Most GLP-1 telehealth platforms use 503A pharmacies
503B: Outsourcing Facilities
Created by Congress in 2013 following a fungal meningitis outbreak traced to a contaminated compounded product. The category was designed to bring larger-scale compounding under federal oversight.
- Registers with the FDA and is subject to FDA inspection
- Must follow current good manufacturing practice (cGMP) requirements
- Can compound in batches without patient-specific prescriptions
- Reports adverse events to the FDA
On paper 503B carries more federal oversight. That does not automatically make any given 503B product better than any given 503A product — a well-run 503A pharmacy with rigorous testing can be excellent, and FDA registration is not a guarantee. But 503B does mean someone federal is inspecting the facility.
What This Means for GLP-1 Buyers
Three practical takeaways when you are comparing providers:
- Being told the category at all is a good sign. Most platforms say only “licensed US pharmacies”. Naming 503A or 503B is a step up; naming the actual pharmacy is better still.
- Neither category is FDA-approved medicine. This is the point that gets blurred most often. A compounded drug from a 503B facility is still not an FDA-approved product — the facility is inspected, the drug is not reviewed.
- Ask about testing, not just category. A certificate of analysis reporting potency, purity, sterility and endotoxins tells you more about your actual vial than the regulatory bucket the pharmacy sits in.
The 2026 Regulatory Shift
This landscape is moving. In 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, on the basis that the shortages which justified large-scale compounding have resolved. Several compounding operations stopped producing GLP-1s as a result. If you are choosing a compounded provider, ask directly whether their supply is affected — a programme that cannot fill your prescription in six months is not a saving.
Questions Worth Asking
- Which pharmacy fills my prescription, by name?
- Is it a 503A pharmacy or a 503B outsourcing facility?
- Can I see a certificate of analysis for the batch I receive?
- Has the pharmacy had any FDA enforcement action?
- What happens to my supply if regulations change?
Providers that answer these readily are listed in our transparency rankings. If avoiding the question entirely appeals more, manufacturer-direct GLP-1s involve no compounding pharmacy at all.